Parasitic helminth infections and the control of human allergic and autoimmune disorders

Clinical Microbiology and Infection

Volumn 22, Issue 6, 2016, Pages 481-486

  Maizels, R M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Allergy; autoimmunity; helminth therapy; hygiene hypothesis; inflammatory bowel disease

Indexed keywords

ALLERGIC DISEASE; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; DISEASE CONTROL; HELMINTH; HELMINTHIASIS; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW; THERAPY WITH HELMINTHS; AUTOIMMUNE DISEASES; CLINICAL TRIAL (TOPIC); HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HELMINTHIASIS; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE;

EID: 84973438720     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.04.024     Document Type: Review

References (76)

1. [1] Maizels, R.M., Yazdanbakhsh, M., T-cell regulation in helminth parasite infections: implications for inflammatory diseases. Chem Immunol Allergy 94 (2008), 112–123.
2. [2] Asher, M.I., Montefort, S., Bjorksten, B., Lai, C.K., Strachan, D.P., Weiland, S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet 368 (2006), 733–743.
3. [3] Gale, E.A., The rise of childhood type 1 diabetes in the 20th century. Diabetes 51 (2002), 3353–3361.
4. [4] Economou, M., Pappas, G., New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 14 (2008), 709–720.
5. [5] Velasquez-Manoff, M., An epidemic of absence: a new way of understanding allergies and autoimmune diseases. 2013, Scribner, New York.
6. [6] Thorburn, A.N., Macia, L., Mackay, C.R., Diet, metabolites, and ‘western-lifestyle’ inflammatory diseases. Immunity 40 (2014), 833–842.
7. [7] McKay, D.M., The therapeutic helminth?. Trends Parasitol 25 (2009), 109–114.
8. [8] McSorley, H.J., Maizels, R.M., Helminth infections and host immune regulation. Clin Micro Rev 25 (2012), 585–608.
9. [9] Hotez, P.J., Brindley, P.J., Bethony, J.M., King, C.H., Pearce, E.J., Jacobson, J., Helminth infections: the great neglected tropical diseases. J Clin Invest 118 (2008), 1311–1321.
10. [10] King, C.H., It's time to dispel the myth of ‘asymptomatic’ schistosomiasis. PLoS Negl Trop Dis, 9, 2015, e0003504.
11. [11] Maizels, R.M., Yazdanbakhsh, M., Regulation of the immune response by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 3 (2003), 733–743.
12. [12] Colley, D.G., Garcia, A.A., Lambertucci, J.R., Parra, J.C., Katz, N., Rocha, R.S., et al. Immune responses during human schistosomiasis. XII. Differential responsiveness in patients with hepatosplenic disease. Am J Trop Med Hyg 35 (1986), 793–802.
13. [13] Sartono, E., Kruize, Y.C.M., Kurniawan, A., van der Meide, P.H., Partono, F., Maizels, R.M., et al. Elevated cellular responses and interferon-γ release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis. J Infect Dis 171 (1995), 1683–1687.
14. [14] Mahanty, S., Mollis, S.N., Ravichandran, M., Abrams, J.S., Kumaraswami, V., Jayaraman, K., et al. High levels of spontaneous and parasite antigen-driven interleukin-10 production are associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. J Infect Dis 173 (1996), 769–773.
15. [15] Babu, S., Bhat, S.Q., Pavan Kumar, N., Lipira, A.B., Kumar, S., Karthik, C., et al. Filarial lymphedema is characterized by antigen-specific Th1 and Th17 proinflammatory responses and a lack of regulatory T cells. PLoS Negl Trop Dis, 3, 2009, e420.
16. [16] Mbow, M., Larkin, B.M., Meurs, L., Wammes, L.J., de Jong, S.E., Labuda, L.A., et al. T-helper 17 cells are associated with pathology in human schistosomiasis. J Infect Dis 207 (2013), 186–195.
17. [17] Platts-Mills, T.A., Woodfolk, J.A., Erwin, E.A., Aalberse, R., Mechanisms of tolerance to inhalant allergens: the relevance of a modified Th2 response to allergens from domestic animals. Springer Semin Immunopathol 25 (2004), 271–279.
18. [18] Kurniawan, A., Yazdanbakhsh, M., van Ree, R., Aalberse, R., Selkirk, M.E., Partono, F., et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol 150 (1993), 3941–3950.
19. [19] Jeannin, P., Lecoanet, S., Delneste, Y., Gauchat, J.F., Bonnefoy, J.Y., IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 160 (1998), 3555–3561.
20. [20] Watanabe, K., Mwinzi, P.N., Black, C.L., Muok, E.M., Karanja, D.M., Secor, W.E., et al. T regulatory cell levels decrease in people infected with Schistosoma mansoni on effective treatment. Am J Trop Med Hyg 77 (2007), 676–682.
21. [21] Wammes, L.J., Hamid, F., Wiria, A.E., Wibowo, H., Sartono, E., Maizels, R.M., et al. Regulatory T cells in human lymphatic filariasis: stronger functional activity in microfilaremics. PLoS Negl Trop Dis, 6, 2012, e1655.
22. [22] Metenou, S., Nutman, T., Regulatory T cell subsets in filarial infection and their function. Front Immunol, 4, 2013, 305.
23. [23] Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
24. [24] Maizels, R.M., Smith, K.A., Regulatory T cells in infection. Adv Immunol 112 (2011), 73–136.
25. [25] Correale, J., Farez, M., Razzitte, G., Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol 64 (2008), 187–199.
26. [26] Hussaarts, L., van der Vlugt, L.E., Yazdanbakhsh, M., Smits, H.H., Regulatory B-cell induction by helminths: implications for allergic disease. J Allergy Clin Immunol 128 (2011), 733–739.
27. [27] Labeaud, A.D., Malhotra, I., King, M.J., King, C.L., King, C.H., Do antenatal parasite infections devalue childhood vaccination?. PLoS Negl Trop Dis, 3, 2009, e442.
28. [28] Johnston, C.J., McSorley, H.J., Anderton, S.M., Wigmore, S.J., Maizels, R.M., Helminths and immunological tolerance. Transplantation 97 (2014), 127–132.
29. [29] Salgame, P., Yap, G.S., Gause, W.C., Effect of helminth-induced immunity on infections with microbial pathogens. Nat Immunol 14 (2013), 1118–1126.
30. [30] Wammes, L.J., Hamid, F., Wiria, A.E., de Gier, B., Sartono, E., Maizels, R.M., et al. Regulatory T cell in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. Eur J Immunol 40 (2010), 437–442.
31. [31] Mishra, P.K., Palma, M., Bleich, D., Loke, P., Gause, W.C., Systemic impact of intestinal helminth infections. Mucosal Immunol 7 (2014), 753–762.
32. [32] Greenwood, B.M., Autoimmune disease and parasitic infections in Nigerians. Lancet 2 (1968), 380–382.
33. [33] van den Biggelaar, A., van Ree, R., Roderigues, L.C., Lell, B., Deelder, A.M., Kremsner, P.G., et al. Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10. Lancet 356 (2000), 1723–1727.
34. [34] van den Biggelaar, A.H., Rodrigues, L.C., van Ree, R., van der Zee, J.S., Hoeksma-Kruize, Y.C., Souverijn, J.H., et al. Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis 189 (2004), 892–900.
35. [35] McKay, D.M., Not all parasites are protective. Parasite Immunol 37 (2015), 324–332.
36. [36] Araujo, M.I., Lopes, A.A., Medeiros, M., Cruz, A.A., Sousa-Atta, L., Solé, D., et al. Inverse association between skin response to aeroallergen and Schistosoma mansoni infection. Int Arch Allergy Immunol 123 (2000), 145–148.
37. [37] Cooper, P.J., Chico, M.E., Rodrigues, L.C., Ordonez, M., Strachan, D., Griffin, G.E., et al. Reduced risk of atopy among school-age children infected with geohelminth parasites in a rural area of the tropics. J Allergy Clin Immunol 111 (2003), 995–1000.
38. [38] Feary, J., Britton, J., Leonardi-Bee, J., Atopy and current intestinal parasite infection: a systematic review and meta-analysis. Allergy 66 (2011), 569–578.
39. [39] Cooper, P.J., Barreto, M.L., Rodrigues, L.C., Human allergy and geohelminth infections: a review of the literature and a proposed conceptual model to guide the investigation of possible causal associations. Br Med Bull 79–80 (2006), 203–218.
40. [40] Smits, H.H., Hammad, H., van Nimwegen, M., Soullie, T., Willart, M.A., Lievers, E., et al. Protective effect of Schistosoma mansoni infection on allergic asthma depends on intensity and chronicity of infection. J Allergy Clin Immunol 120 (2007), 932–940.
41. [41] Flohr, C., Tuyen, L.N., Quinnell, R.J., Lewis, S., Minh, T.T., Campbell, J., et al. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy 40 (2010), 131–142.
42. [42] Mutapi, F., Imai, N., Nausch, N., Bourke, C.D., Rujeni, N., Mitchell, K.M., et al. Schistosome infection intensity is inversely related to auto-reactive antibody levels. PLoS One, 6, 2011, e19149.
43. [43] Correale, J., Farez, M., Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 61 (2007), 97–108.
44. [44] Correale, J., Farez, M.F., The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol 233 (2011), 6–11.
45. + T cells are associated with therapeutic Trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med, 2, 2010, 60ra88.
46. [46] Weinstock, J.V., Elliott, D.E., Translatability of helminth therapy in inflammatory bowel diseases. Int J Parasitol 43 (2013), 245–251.
47. [47] Fleming, J.O., Weinstock, J.V., Clinical trials of helminth therapy in autoimmune diseases: rationale and findings. Parasite Immunol 37 (2015), 277–292.
48. [48] Summers, R.W., Elliott, D.E., Qadir, K., Urban, J.F. Jr., Thompson, R., Weinstock, J.V., Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98 (2003), 2034–2041.
49. [49] Summers, R.W., Elliott, D.E., Urban, J.F. Jr., Thompson, R.A., Weinstock, J.V., Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005), 825–832.
50. [50] Summers, R.W., Elliott, D.E., Urban, J.F. Jr., Thompson, R., Weinstock, J.V., Trichuris suis therapy in Crohn's disease. Gut 54 (2005), 87–90.
51. [51] Garg, S.K., Croft, A.M., Bager, P., Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev, 1, 2014, CD009400.
52. [52] Bager, P., Arnved, J., Rønborg, S., Wohlfahrt, J., Poulsen, L.K., Westergaard, T., et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 125 (2010), 123–130.
53. [53] Bourke, C.D., Mutapi, F., Nausch, N., Photiou, D.M., Poulsen, L.K., Kristensen, B., et al. Trichuris suis ova therapy for allergic rhinitis does not affect allergen-specific cytokine responses despite a parasite-specific cytokine response. Clin Exp Allergy 42 (2012), 1582–1595.
54. [54] Jouvin, M.H., Kinet, J.P., Trichuris suis ova: testing a helminth-based therapy as an extension of the hygiene hypothesis. J Allergy Clin Immunol 130 (2012), 3–10.
55. [55] Benzel, F., Erdur, H., Kohler, S., Frentsch, M., Thiel, A., Harms, L., et al. Immune monitoring of Trichuris suis egg therapy in multiple sclerosis patients. J Helminthol 86 (2012), 339–347.
56. [56] Fleming, J., Isaak, A., Lee, J., Luzzio, C., Carrithers, M., Cook, T.D., et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 17 (2011), 743–754.
57. [57] Voldsgaard, A., Bager, P., Garde, E., Akeson, P., Leffers, A.M., Madsen, C.G., et al. Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Mult Scler 21 (2015), 1723–1729.
58. [58] Fleming, J., Hartman, L., Maksimovic, J., Nace, S., Luzzio, C., Koehn, M., et al. Clinical trial of helminth-induced immunomodulatory therapy (HINT 2) in relapsing-remitting multiple sclerosis. Neurology, 82(Suppl P3), 2014, 149.
59. [59] Feary, J., Venn, A., Brown, A., Hooi, D., Falcone, F.H., Mortimer, K., et al. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clin Exp Allergy 39 (2009), 1060–1068.
60. [60] Feary, J.R., Venn, A.J., Mortimer, K., Brown, A.P., Hooi, D., Falcone, F.H., et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy 40 (2010), 299–306.
61. [61] Croese, J., O'Neil, J., Masson, J., Cooke, S., Melrose, W., Pritchard, D., et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 55 (2006), 136–137.
62. [62] Daveson, A.J., Jones, D.M., Gaze, S., McSorley, H., Clouston, A., Pascoe, A., et al. Effect of hookworm infection on wheat challenge in celiac disease—a randomised double-blinded placebo controlled trial. PLoS One, 6, 2011, e17366.
63. [63] Evans, H., Mitre, E., Worms as therapeutics for allergy: understanding why benefits in animal studies have not translated into clinical success. J Allergy Clin Immunol 135 (2015), 343–353.
64. [64] Helmby, H., Human helminth therapy to treat inflammatory disorders—where do we stand?. BMC Immunol, 16, 2015, 12.
65. [65] Leonardi, I., Frey, I., Rogler, G., Helminth therapy for organic diseases?. Transl Res 166 (2015), 586–601.
66. [66] Finlay, C.M., Walsh, K.P., Mills, K.H., Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. Immunol Rev 259 (2014), 206–230.
67. [67] Johnston, M.J.G., Macdonald, J.A., McKay, D.M., Parasitic helminths: a pharmacopeia of anti-inflammatory molecules. Parasitology 136 (2009), 125–147.
68. [68] Heylen, M., Ruyssers, N.E., Gielis, E.M., Vanhomwegen, E., Pelckmans, P.A., Moreels, T.G., et al. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease. Pharmacol Ther 143 (2014), 153–167.
69. [69] Harnett, W., Harnett, M.M., Helminth-derived immunomodulators: can understanding the worm produce the pill?. Nat Rev Immunol 10 (2010), 278–284.
70. [70] McSorley, H.J., Hewitson, J.P., Maizels, R.M., Immunomodulation by helminth parasites: defining mechanisms and mediators. Int J Parasitol 43 (2013), 301–310.
71. [71] Shepherd, C., Navarro, S., Wangchuk, P., Wilson, D., Daly, N.L., Loukas, A., Identifying the immunomodulatory components of helminths. Parasite Immunol 37 (2015), 293–303.
72. [72] Hewitson, J.P., Grainger, J.R., Maizels, R.M., Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol 167 (2009), 1–11.
73. [73] Schnoeller, C., Rausch, S., Pillai, S., Avagyan, A., Wittig, B.M., Loddenkemper, C., et al. A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages. J Immunol 180 (2008), 4265–4272.
74. [74] Harnett, M.M., Melendez, A.J., Harnett, W., The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin Exp Immunol 159 (2010), 256–267.
75. [75] Navarro, S., Ferreira, I., Loukas, A., The hookworm pharmacopoeia for inflammatory diseases. Int J Parasitol 43 (2013), 225–231.
76. [76] McSorley, H.J., Blair, N.F., Smith, K.A., McKenzie, A.N.J., Maizels, R.M., Blockade of IL-33 release and suppression of type 2 innate lymphoid cell responses by helminth secreted products in airway allergy. Mucosal Immunol 7 (2014), 1068–1078.